One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found.
A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) blocked infection when tested in human cells in a laboratory setting.
UC San Diego will be one of multiple sites assessing the safety and efficacy of tecovirimat as a potential treatment for human monkeypox. Marketed as TPOXX, tecovirimat is an antiviral currently approved for treatment of human smallpox in adults and children caused by the variola virus.
UW Medicine researchers compared vaginal samples collected from 95 young women or adolescent study participants in Kenya before or after they began having sexual intercourse. They found a sharp increase in proteins that control the immune response, including IL-1β, IL-2, and CXCL8, during the first year after becoming sexually active.
The GW School of Medicine and Health Sciences is recruiting participants for the final stage of a clinical trial to evaluate two Omicron-specific vaccines. The study, known as the COVID-19 Variant Immunologic Landscape (COVAIL) trial, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The George Washington University School of Medicine and Health Sciences has received funding support as an agreement under NIH contract number 75N91019D00024 to Leidos Biomedical Research in Frederick, Maryland.
Researchers have identified the gene TDRD7 as a key regulator against influenza A virus (IAV), which causes respiratory tract infections in 5 to 20 percent of the human population.
New UCLA-led research suggests certain gut bacteria -- including one that is essential for a healthy gut microbiome – differ between people who go on to acquire HIV infection compared to those who have not become infected. The findings, published in the peer-reviewed journal eBioMedicine, suggest that the gut microbiome could contribute to one’s risk for HIV infection, said study lead Dr.
Irvine, Calif., Sept. 26, 2022 – The University of California, Irvine has been awarded a five-year, $13.8 million contract from the National Institute of Allergy and Infectious Diseases to conduct detailed immune profiling of lipid nanoparticles to increase understanding of their role in enhancing vaccine protective responses and in causing side effects.
Lessons learned from the public health responses to the HIV and COVID-19 pandemics should help guide the response to the current outbreak of monkeypox, National Institutes of Health experts write in an editorial published today in the New England Journal of Medicine.
With COVID-19 vaccines pushing down costs of mRNA technology, a study in mice from Cummings School of Veterinary Medicine experts sparks hope for next generation treatments and potential applications to developing world and veterinary diseases
Cedars-Sinai investigators have developed a method to help identify which human gut microbes are most likely to contribute to a slew of inflammatory diseases like obesity, liver disease, inflammatory bowel disease, cancer and some neurological diseases.
One injection of a candidate monoclonal antibody (mAb) known as L9LS was found to be safe and highly protective in U.S. adults exposed to the malaria parasite, according to results from a National Institutes of Health Phase 1 clinical trial published in The New England Journal of Medicine.
Johns Hopkins Medicine scientists report they have probed the atomic structure of proteins to add to evidence that the wobbles, shakes and quivers of proteins play a critical role in their ability to function. The findings of the research may help scientists design new drugs that can modify or disrupt the intricate “dances” of proteins to alter their functions.
UNC School of Medicine scientists discovered that hepatitis A viral replication requires specific interactions between a human protein and a group of enzymes, and they used a molecule to stop replication at this key interactive step, making it impossible for the virus to infect liver cells.
The virus that causes COVID-19 takes over the body’s fat-processing system and boosts cellular triglycerides as it causes disease.
A collaborative study from UT Southwestern scientists has identified a new function for a protein called TAO2 that appears to be key to inhibiting replication of the influenza virus, which sickens millions of individuals worldwide each year and kills hundreds of thousands. The findings were published in PNAS.
"Just understanding the immune responses to these vaccines will help us integrate what is successful into vaccine designs going forward.”
Consortium of Hackensack Meridian CDI, Rockefeller University, Columbia University, Memorial Sloan Kettering Cancer Center, Rutgers University, Merck, Tri-Institutional Therapeutics Discovery Institute, Inc., and Aligos Therapeutics to combine expertise to ‘accelerate’ new breakthroughs
University of Maryland School of Medicine (UMSOM)’s Institute of Human Virology (IHV) researchers received funding from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) for $2.7 million to study genetic changes in two genes from the HIV-1 virus that may make it resistant to antiretroviral therapy.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID) and White House Chief Medical Advisor, will present “COVID-19: Progress and Priorities in the 3rd Year of a Historic Pandemic” when he delivers the 2022 David Packard Award Lecture at the Uniformed Services University of the Health Sciences (USU), Monday, April 11, 2022.
The team's latest study, published in Cell, shows that two clever human antibodies can target two ebolavirus species at once: Ebola virus and Sudan virus. These two species are responsible for the biggest, deadliest outbreaks. The new report suggests researchers could combine these two potent antibodies to make a powerful antiviral therapy.
Using mRNA technology like that in the COVID-19 vaccines, researchers have demonstrated a successful way to deliver a potential HIV vaccine, researchers at Duke Human Vaccine Institute report.
The first 12 study participants have been enrolled in a new Phase 1 clinical trial using the messenger ribonucleic acid (mRNA) vaccine technology developed by Moderna. The study evaluates the safety of and immune responses to three different experimental vaccines against HIV. This randomized, open-label trial represents one of the first clinical studies of the use of mRNA vaccine technology against HIV.
In a new article published in the March issue of Emerging Infectious Diseases, Moffitt researchers set out to estimate the percentage of Hillsborough County residents who had COVID infection and better understand demographics and behavioral factors associated with infection.
People who gained immunity — either through vaccination or exposure — against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant, says an international research team from Johns Hopkins Medicine.
Mice that received treatments with peanut-coated microneedles had significant increased rates of desensitization to peanut allergy compared with epicutaneous immunotherapy (EPIT), a new study found. The microneedle treatment success was achieved despite applying a dose of peanut protein 10-times lower than the dose delivered by EPIT. Researchers say the findings demonstrate the potential for peanut microneedles to improve food allergen immunotherapy through the skin.
Researchers at the Uniformed Services University in collaboration with University of Washington, have recently uncovered new details about how Nipah and Hendra viruses infect cells and the immune responses that can block them, which could ultimately lead to the development of new tactics to prevent and treat these deadly illnesses.
A Stony Brook University physician-scientist has identified that mucosal-associated invariant T (MAIT) cells exercise several complex roles during healthy and disease states. The published findings may help to serve as a benchmark for future research on MAIT cells as targets for immunotherapies and vaccines.
A team led by UCLA researchers will receive a multi-million dollar grant to study why some people suffer from a devastating fungal infection called Valley Fever, while others suffer seemingly no impact from the disease.
Five days of antibiotics is superior to 10 days for children with community-acquired pneumonia who are not hospitalized, according to a study published in JAMA Pediatrics.
.jpg&width=400&height=400)
In preliminary studies, CHLA researchers have found that increasing the activity of a specific gene inside T-cells makes the T-cells stronger and longer-lasting. This line of research could lead to broader applications for CAR T-cell therapy in treating other cancers that have not responded to this therapy in the past. Chintan Parekh, MD, a physician scientist in the Cancer and Blood Disease Institute at Children’s Hospital Los Angeles, has received a five-year, $2.3 million grant from the National Institute of Allergy and Infectious Diseases to pursue this line of research further.
The National Institute of Allergy and Infectious Diseases awarded researchers at the Duke Human Vaccine Institute a contract that enables it to compete for projects advancing investigational vaccines to production for use in early clinical trials.
Physicians at Washington University School of Medicine in St. Louis and Massachusetts General Hospital/Harvard Medical School in Boston have received a seven-year, $22 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to help lead a multicenter clinical trial evaluating whether a novel immunosuppressant can reduce the risk of organ rejection after a lung transplant.
Binghamton University Chemistry Professor Eriks Rozners has received a two-year $428,330 grant from the National Institute of Allergy and Infectious Diseases for a research project which explores the "switch" behind the coronavirus.
In a newly published study, researchers at the University of Maryland School of Medicine have detected antibodies primarily made in response to infections in the mucous membranes — in such areas as the lungs, intestines, or vagina — in study participants with malaria.
A research collaboration between scientists at Duke University and the University of North Carolina at Chapel Hill has identified and tested an antibody that limits the severity of infections from a variety of coronaviruses, including those that cause COVID-19 as well as the original SARS illness.
In what is believed to be one of the largest studies of its kind, Johns Hopkins Medicine researchers have shown that antibody levels against SARS-CoV-2 (the COVID-19 virus) stay more durable — that is, remain higher over an extended period of time — in people who were infected by the virus and then received protection from two doses of messenger RNA (mRNA) vaccine compared with those who only got immunized.
A booster dose of the mRNA-1273 COVID-19 vaccine given to rhesus macaques about six months after their primary vaccine series significantly increased levels of neutralizing antibodies against all known SARS-CoV-2 variants of concern, according to a new study from National Institutes of Health scientists and colleagues.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded $17.5 million over three years to the Duke Human Vaccine Institute to develop a vaccine that protects against multiple types of coronaviruses and viral variants.
Wistar is proud to announce Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH); Jane Shull, chief executive officer of Philadelphia FIGHT; philanthropist Ken Nimblett; Philadelphia Foundation and the Robert I. Jacobs Fund; and Philadelphia FIGHT will be honored at the Wistar Legacy Awards, a celebration of 25 years of continuous HIV research collaboration on Thursday, October 28 from 5:30 to 7:45 p.m.
Researcher-physicians at Beth Israel Deaconess Medical Center used a novel, highly-sensitive test to measure the amount of toxin produced by C. difficile in the stool of patients with suspected infections.
Iowa State researchers affiliated with the Nanovaccine Institute have explained how a nanomaterial initiates antibody production by the immune system's B cells. The technique could be used to turn B cells into factories that provide antibodies for diagnostic tests or treatments.
A new therapeutic era has been ushered in with Adoptive Cell Immunotherapy, which uses patient-harvested T cells genetically engineered against tumor-specific targets.
At a time when incidence of Lyme disease is rising across the U.S., a study led by University of Kentucky College of Medicine researcher Brian Stevenson, Ph.D., may provide a significant impact in the fight against the disease. A new study will build upon Stevenson's three decades of research aimed at understanding Borrelia burgdorferi, the bacteria that causes Lyme disease.
The gut microbiome can impact us in a variety of different ways, from our metabolism to our mood. Now, NIBIB-funded researchers are investigating if a fiber-based gel can restore beneficial microbes in the gut to enhance the efficacy of immune checkpoint inhibitors, a type of cancer immunotherapy treatment, in mice.
A recent study led by an Iowa State University entomologist explores the different kinds of cells that make up mosquito immune systems. The research could shed light on how mosquitoes transmit malaria.
A new study from the Perelman School of Medicine at the University of Pennsylvania shows how to overcome resistance to CAR T cell therapy with an experimental small molecule inhibitor.
UC San Diego researchers modify remdesivir, creating oral version that can be taken earlier in COVID-19 diagnoses. In cell and animal studies, revised drug proved effective and safe.
Two different strategies to discover and perfect pharmaceuticals active against the COVID-19 virus have attracted a half million dollars in research funding to support five institutions, including the Baudry Lab at The University of Alabama in Huntsville (UAH).
People who are just beginning treatment for high blood pressure can benefit equally from two different classes of medicine - angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) - yet ARBs may be less likely to cause medication side effects, according to an analysis of real-world data published today in Hypertension, an American Heart Association journal.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
